Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Cullinan Therapeutics Analyst Ratings and Price Targets | NASDAQ:CGEM | Benzinga
Cullinan Therapeutics Inc has a consensus price target of $32 based on the ratings of 9 analysts. The high is $40 issued by Stifel on May 1, 2024. The low is $24 issued by UBS on May 12, 2025. The 3 most-recent analyst ratings were released by UBS, HC Wainwright & Co., and Morgan Stanley on May 12, 2025, April 16, 2025, and March 7, 2025, respectively. With an average price target of $30.67 between UBS, HC Wainwright & Co., and Morgan Stanley, there's an implied 258.67% upside for Cullinan Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
HC Wainwright & Co.
Morgan Stanley
Wedbush
Stifel
1calculated from analyst ratings
Analyst Ratings for Cullinan Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/12/2025 | Buy Now | 180.7% | UBS | David Dai26% | $30 → $24 | Maintains | Buy | Get Alert |
| 04/16/2025 | Buy Now | 285.96% | HC Wainwright & Co. | Edward White48% | $33 → $33 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2025 | Buy Now | 309.36% | Morgan Stanley | Jeffrey Hung50% | $38 → $35 | Assumes | → Overweight | Get Alert |
| 02/28/2025 | Buy Now | 285.96% | HC Wainwright & Co. | Edward White48% | $33 → $33 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2025 | Buy Now | 285.96% | HC Wainwright & Co. | Edward White48% | $28 → $33 | Maintains | Buy | Get Alert |
| 10/24/2024 | Buy Now | 250.88% | UBS | David Dai26% | → $30 | Initiates | → Buy | Get Alert |
| 10/16/2024 | Buy Now | 227.49% | HC Wainwright & Co. | Edward White48% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2024 | Buy Now | 321.05% | Wedbush | Robert Driscoll44% | $36 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 09/17/2024 | Buy Now | 227.49% | HC Wainwright & Co. | Edward White48% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 227.49% | HC Wainwright & Co. | Edward White48% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 321.05% | Wedbush | Robert Driscoll44% | $36 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 06/03/2024 | Buy Now | 227.49% | HC Wainwright & Co. | Edward White48% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 227.49% | HC Wainwright & Co. | Edward White48% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 321.05% | Wedbush | Robert Driscoll44% | $36 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 05/16/2024 | Buy Now | 227.49% | HC Wainwright & Co. | Edward White48% | $29 → $28 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 367.84% | Stifel | Bradley Canino40% | → $40 | Initiates | → Buy | Get Alert |
| 04/17/2024 | Buy Now | 204.09% | JonesTrading | Soumit Roy34% | $22 → $26 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 250.88% | BTIG | Kaveri Pohlman25% | $20 → $30 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 239.18% | HC Wainwright & Co. | Edward White48% | $34 → $29 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | — | William Blair | Matt Phipps25% | — | Initiates | → Outperform | Get Alert |
| 03/14/2024 | Buy Now | 297.66% | HC Wainwright & Co. | Edward White48% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 02/15/2024 | Buy Now | 250.88% | Wedbush | Robert Driscoll44% | → $30 | Initiates | → Outperform | Get Alert |
| 10/06/2023 | Buy Now | 157.31% | JonesTrading | Soumit Roy34% | → $22 | Initiates | → Buy | Get Alert |
| 08/11/2023 | Buy Now | 297.66% | HC Wainwright & Co. | Edward White48% | $49 → $34 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 473.1% | HC Wainwright & Co. | Edward White48% | → $49 | Reiterates | → Buy | Get Alert |
| 07/07/2023 | Buy Now | 473.1% | HC Wainwright & Co. | Edward White48% | → $49 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | — | TD Cowen | Marc Frahm23% | — | Initiates | → Outperform | Get Alert |
| 06/05/2023 | Buy Now | 473.1% | HC Wainwright & Co. | Edward White48% | → $49 | Reiterates | Buy → Buy | Get Alert |
| 05/26/2023 | Buy Now | 473.1% | HC Wainwright & Co. | Edward White48% | → $49 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 473.1% | HC Wainwright & Co. | Edward White48% | $50 → $49 | Maintains | Buy | Get Alert |
| 03/27/2023 | Buy Now | 484.8% | HC Wainwright & Co. | Edward White48% | → $50 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 484.8% | HC Wainwright & Co. | Edward White48% | → $50 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | 484.8% | HC Wainwright & Co. | Edward White48% | → $50 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | 122.22% | Morgan Stanley | Jeffrey Hung50% | $27 → $19 | Maintains | Overweight | Get Alert |
| 11/21/2022 | Buy Now | 133.92% | BTIG | Kaveri Pohlman25% | → $20 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Cullinan Therapeutics (CGEM) stock?
The latest price target for Cullinan Therapeutics (NASDAQ:CGEM) was reported by UBS on May 12, 2025. The analyst firm set a price target for $24.00 expecting CGEM to rise to within 12 months (a possible 180.70% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cullinan Therapeutics (CGEM)?
The latest analyst rating for Cullinan Therapeutics (NASDAQ:CGEM) was provided by UBS, and Cullinan Therapeutics maintained their buy rating.
When was the last upgrade for Cullinan Therapeutics (CGEM)?
There is no last upgrade for Cullinan Therapeutics
When was the last downgrade for Cullinan Therapeutics (CGEM)?
There is no last downgrade for Cullinan Therapeutics.
When is the next analyst rating going to be posted or updated for Cullinan Therapeutics (CGEM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cullinan Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cullinan Therapeutics was filed on May 12, 2025 so you should expect the next rating to be made available sometime around May 12, 2026.
Is the Analyst Rating Cullinan Therapeutics (CGEM) correct?
While ratings are subjective and will change, the latest Cullinan Therapeutics (CGEM) rating was a maintained with a price target of $30.00 to $24.00. The current price Cullinan Therapeutics (CGEM) is trading at is $8.55, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
